Showing results (31-40 of 40) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
European Heart Journal|November 5, 2010
Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE studyGuido Grassi, Renata Cifkova, Stephane Laurent, et al.American Heart Journal|April 25, 2007
Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified TitrationLuis Miguel Blanco-Colio, Jose Luis Martín-Ventura, Eduardo de Teresa, et al.Kidney International. Supplement|November 27, 2008
Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFASTLuis M Blanco-Colio, Jose L Martín-Ventura, Eduardo de Teresa, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|October 21, 2006
Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFASTLuis M Blanco-Colio, Jose L Martín-Ventura, Eduardo de Teresa, et al.Plos One|April 4, 2015
Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudyScott J Denardo, Yan Gong, Rhonda M Cooper-DeHoff, et al.European Journal of Pharmacology|April 1, 2008
Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular riskLuis M Blanco-Colio, Jose L Martín-Ventura, Carmen Gómez-Guerrero, et al.Plos One|June 4, 2016
Correction: Effects of Verapamil SR and Atenolol on 24-Hour Blood Pressure and Heart Rate in Hypertension Patients with Coronary Artery Disease: An International Verapamil SR-Trandolapril Ambulatory Monitoring SubstudyScott J Denardo, Yan Gong, Rhonda M Cooper-DeHoff, et al.Journal of Clinical Pharmacology|May 26, 2011
Low-density lipoprotein cholesterol and high-sensitivity C-reactive protein lowering with atorvastatin in patients of South Asian compared with European origin: insights from the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) studyMilan Gupta, Pierre Martineau, Thang Tran, et al.Journal of Hypertension|July 1, 2014
Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trialAlberto Zanchetti, Lisheng Liu, Giuseppe Mancia, et al.Journal of Hypertension|July 1, 2014
Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidenceAlberto Zanchetti, Lisheng Liu, Giuseppe Mancia, et al.Pageof 4